ClinicalTrials.gg
Active, not recruitingNCT04594798Updated Sep 18, 2026

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

A Phase 2 interventional study of Polatuzumab vedotin and Rituximab in DLBCL and Lymphoma, B-Cell, sponsored by University of Rochester. Active, not recruiting at 1 site in United States. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by University of Rochester · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell — 5 open to participants now, 8 under way, none of them phase 3. polatuzumab vedotin · Lymphoma, B-Cell.

Planned enrollment
7th of 11
39 · median 40
Started
2021
with 3 others
Phase 2
7 of 11
4 open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
University of Rochester

Among the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell, this one is the 7th largest by planned enrollment, is one of 4 that started in 2021, is one of 7 in phase 2, and was the 4th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

5 of the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About polatuzumab vedotin

polatuzumab vedotin: first FDA approval 2019 (POLIVY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to test the effectiveness and safety of polatuzumab vedotin in combination with R-miniCHP in patients 75 years and older with DLBCL.

Read the detailed description

In this study, the investigator would like to better understand the efficacy and safety of the addition of polatuzumab vedotin to therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) and dose attenuated R-CHOP in patients who are aged 75 years and older.

03

Conditions studied

  • DLBCL
  • Lymphoma, B-Cell

Browse trials for

Keywords

  • polatuzumab vedotin
  • rituximab
  • cyclophosphamide
  • doxorubicin
  • prednisone
  • R-miniCHP
  • DLBCL
  • Lymphoma, B-Cell
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written before performance of any study-specific procedure not part of routine medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. Subjects must be able to understand and be willing to sign the written informed consent form.
  • Men and women aged greater than or equal to 75 years of age
  • performance status of 0-3
  • -confirmed DLBCL, NOS, NOS, high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements, high grade B-cell lymphoma, NOS, and grade 3b follicular lymphoma by 2016 WHO classification by site hematopathologist

    • Histologic transformation (HT) will be included on the study. This must be confirmed with a . Patients with HT may have received prior treatment for indolent lymphoma including chemoimmunotherapy, but must not have received an anthracycline-containing regimen in the past. Patients with Richter's transformation will be eligible.
    • Composite and discordant lymphomas containing both indolent and large cell features will be included
  • Has received no prior therapy for aggressive B-cell lymphoma or HT with the following exceptions:

    • A course of given for lymphoma related symptoms.
    • A course of cyclophosphamide or vincristine with or without steroids given for lymphoma related symptoms.
    • One cycle of anthracycline containing chemotherapy such as R-CHOP or R-miniCHOP given urgently for aggressive disease.

Patient is not felt to be a candidate for standard dose R-CHOP due to age or comorbidities, per the site investigator.

  • of ≥ 45% on echocardiogram or MUGA
  • Patient has a count of ≥75,000/μL within 14 days before enrollment unless inadequate function is due to bone marrow infiltration with aggressive B-cell lymphoma
  • Patient has an of ≥1,500/ μL within 14 days before enrollment unless inadequate function is due to bone marrow infiltration with aggressive B-cell lymphoma
  • Patient has a calculated or measured of >30 mL/minute within 14 days before enrollment.
  • Total must be less than 1.5 times the (ULN) unless the elevation is known to be due to Gilbert syndrome or hepatic involvement with aggressive B-cell lymphoma in which case it can be ≤ 3.0 times the ULN.
  • or AST must be ≤ 2.5 times the ULN.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:

    • With female partners of or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 5 months after the last dose of polatuzumab vedotin to avoid exposing the embryo or fetus for the duration of the pregnancy. Men must refrain from donating sperm during this same period.
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of preventing drug exposure. Male patients considering preservation of fertility should bank sperm before study treatment.

Exclusion criteria

Exclusion Criteria:

  • History of, or clinically apparent central nervous system (CNS) lymphoma
  • Primary mediastinal B-cell lymphoma or EBV positive DLBCL
  • Patient is receiving peritoneal dialysis or hemodialysis
  • Patient has > Grade 1 peripheral neuropathy.
  • class III heart failure or EF \<45%
  • Patient has received other drugs with 14 days before enrollment
  • Prior exposure to anthracycline except for one cycle of therapy given urgently for lymphoma.
  • Patient has concomitant active that the treating physician or PI feels may interfere with the ability to measure the primary or secondary outcomes

    • Patients with stage 1 cancers are eligible after definitive treatment.
    • Patients with low grade prostate cancer who are managed with observation are eligible.
    • Patients with other malignancies that have been treated with curative intent will be included if they are in documented remission without treatment for ≥ 3 years prior to enrollment.
  • Patient is known to be positive (test result not required for enrollment).
  • Patient has active with a positive surface antigen or viral load. Carriers of hepatitis B virus should be closely monitored for clinical and laboratory signs of active HBV infection and for signs of hepatitis throughout study participation according to national and local guidelines. Those at high risk of reactivation should be placed on appropriate antiviral therapy as per national guidelines.
  • History of solid organ transplantation, or post-transplant lymphoproliferative disorder
  • Patient has history of stem cell transplantation.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Any abnormality in screening blood chemistry, hematology, or urinalysis results that, in the judgment of the investigator, would impede adequate evaluation of adverse
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Experimental: Polatuzumab Vedotin and R-CHOP

    The dose of polatuzumab vedotin for each patient will be 1.8 mg/kg (IV for 21 days)

    Drug: Polatuzumab vedotin · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival

    Measure of time from study enrollment until progression.

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

Secondary outcomes

  1. Overall Survival

    Measure of time from study enrollment until death from any cause.

    Time frame: From date of enrollment until date of death from any cause up to 24 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jul 2027, 70 months after the start.

Of 94 non-industry phase 2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 70 months is above that.

Counting every sponsor, half of 120 studies reached it within 53 months; a quarter within 34 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2020
First posted
Oct 20, 2020
StartActual
Sep 20, 2021
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04594798
Collaborators
Genentech, Inc.
Responsible party
Patrick Reagan (Assistant Professor - Department of Medicine , Hematology/Oncology (SMD), University of Rochester) — Principal investigator
First posted
Oct 20, 2020
Start date
Sep 20, 2021
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Patrick Reagan
principal investigator · University of Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polatuzumab vedotin · Rituximab

Start the discussion